<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296347</url>
  </required_header>
  <id_info>
    <org_study_id>Chumbley1</org_study_id>
    <nct_id>NCT01296347</nct_id>
  </id_info>
  <brief_title>Low Dose Peri-operative IV Ketamine for Chronic Post-surgery Pain Prevention</brief_title>
  <official_title>A Double-blind, Randomised Placebo-controlled Trial to Determine Whether Low-dose Intravenous Ketamine Peri-operatively Can Prevent Chronic Post-surgical Pain, in Patients Undergoing Thoracotomy or Video Assisted Thoracic Surgery (VATS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College Healthcare NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the null hypothesis that low-dose ketamine given peri-operatively will
      have no effect on the development of chronic post-surgical pain, in patients undergoing
      thoracotomy or video assisted thoracic surgery (VATS) procedures

      A double-blind, randomised placebo-controlled trial will be used to test the null hypothesis.
      Potential participants due to undergo either thoracotomy or video assisted thoracic surgery
      (VATS) will be identified by the collaborating thoracic surgeons in the out-patient
      department. Patients will be sent information about the study by post, prior to admission for
      surgery. If they are willing to participate, written consent will be sought on the ward
      preoperatively, where they will complete baseline measures of pain.

      Patients will be randomised to receive an intravenous infusion of placebo (saline) or
      ketamine running at 0.1mg/kg/hour, starting 10 minutes prior to the surgical incision and
      continuing for the first three postoperative days (96 hours in total). Prior to starting the
      infusion a loading dose of ketamine (0.1 mg per kg) will be administered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test the null hypothesis that low-dose ketamine given peri-operatively will
      have no effect on the development of chronic post-surgical pain, in patients undergoing
      thoracotomy or video assisted thoracic surgery (VATS) procedures

      A double-blind, randomised placebo-controlled trial will be used to test the null hypothesis.
      Potential participants due to undergo either thoracotomy or video assisted thoracic surgery
      (VATS) will be identified by the collaborating thoracic surgeons in the out-patient
      department. Patients will be sent information about the study by post, prior to admission for
      surgery. If they are willing to participate, written consent will be sought on the ward
      preoperatively, where they will complete baseline measures of pain.

      Patients will be randomised to receive an intravenous infusion of placebo (saline) or
      ketamine running at 0.1mg/kg/hour, starting 10 minutes prior to the surgical incision and
      continuing for the first three postoperative days (96 hours in total). Prior to starting the
      infusion a loading dose of ketamine (0.1 mg per kg) will be administered. All staff,
      including the anaesthetist, surgical team, ward nurses and the principal investigator will be
      blind to the treatment given throughout the study. The key to the randomisation will be
      revealed at the end of the study.

      Patients will be asked to complete a numeric pain score (NPS) and standard pain
      questionnaires which includes the Brief Pain Inventory [BPI], short form Leeds Assessment of
      Neuropathic Symptoms and Signs [S-LANSS]) prior to surgery, then at 6 weeks, 3, 6 and 12
      months after surgery. The surgical area will also be examined at 6 weeks, 6 and 12 months for
      signs of neuropathic or nerve pain. Whilst in hospital patients will be asked to score their
      pain daily, on a numeric pain scale of 0 to 10. Consumption of morphine and side-effects will
      be recorded.

      Patients will receive standard post-operative analgesia.

      A sample size calculation based on a previous study, to detect a reduction in pain of 2
      points the 10 point numeric pain scale at the 6 week assessment, with α = 5%, 1 - β = 90% and
      a bilateral hypothesis, would require a sample size of 36 per group, 72 patients in total.
      This will require a total study population of 144 patients, as both video assisted thoracic
      surgery (VATS) and thoracotomy patients will be studied.

      A two samples t-test will be used to compare the numeric pain scores between the ketamine and
      placebo groups at each time point. If these data are not normally distributed then the Mann
      Whitney test will be used. The scores from the Brief Pain Inventory (BPI) and short form
      Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) will be analysed in the same
      manner. The Chi Squared test will be used to compare dichotomous data, such as the incidence
      of side-effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Incidence of Pain</measure>
    <time_frame>6 weeks after surgery</time_frame>
    <description>Measures in pain include:
Numeric pain score of 0 to 10. Zero denotes 'no pain'; 10 denotes 'pain as bad as you can imagine'</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic Consumption</measure>
    <time_frame>24 hours, 48 hours, 6 weeks, 3, 6 and 12 months</time_frame>
    <description>Analgesia consumption will be measured post-operatively and at the time points stated above. The cumulative dose of opioid, measured in oral morphine equivalents, will be obtained from the time of the patient's arrival in recovery (T0), to 24 hours post-operatively (T0 + 24) and to 48 hours post-operatively (T0 + 48). Analgesia consumption will also be measured at six weeks, three months, six months and one year. All analgesia will be converted to oral morphine equivalents (in mg) by multiplication by a factor depending on the analgesia taken (codeine 0.15, tramadol 0.17, oxycodone 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory Testing</measure>
    <time_frame>6 weeks, 6 months, 12 months</time_frame>
    <description>Hypoaesthesia: light touch of the blunt end of a paintbrush was felt less precisely, than in healthy tissue.
Hyperalgesia: the pain induced by a sterile neurotip, applied perpendicular to the skin is felt abnormally strongly, in comparison to the contralateral side.
Static allodynia: the application of a Von Frey hair number 14. (8g) was unpleasant, in comparison to the contralateral side.
Dynamic allodynia: three successive gentle strokes of an 8 mm-wide paintbrush over a 40 mm distance, is unpleasant, in comparison to the contralateral side.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Side-effects</measure>
    <time_frame>24 hours, 48 hours</time_frame>
    <description>The presence of nausea, vomiting, itching, sedation, feeling lightheaded or vivid dreams will be recorded at the above time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Pain</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Measures in pain include:
Numeric pain score of 0 to 10. Zero denotes 'no pain'; 10 denotes 'pain as bad as you can imagine' Brief Pain Inventory (BPI) Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Chronic Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive a placebo infusion of 0.9% sodium chloride, which will start 10 minutes prior to the start of the operation and continue for 96 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intravenous ketamine, starting 10 minutes prior to surgery and will continue for 96 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion</description>
    <arm_group_label>ketamine</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult patients (18 years and above) who are undergoing either thoracotomy or video
             assisted thoracic surgery (VATS).

          -  Participants must be able to understand English.

        Exclusion Criteria:

          -  Patient refusal

          -  History of previous chronic thoracic pain

          -  Neuropathic pain (whatever the site), existing at time of recruitment

          -  Pre-operative analgesic treatments which include the following medications: strong
             opioids (step 3 analgesics), tricyclic antidepressants, venlafaxine, gabapentin,
             pregabalin, duloxetine, clonazepam or carbamazepine.

          -  Allergy to bupivacaine, morphine, paracetamol, tramadol, dihydrocodeine or ketamine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gillian M Chumbley, BSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial Healthcare NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <results_first_submitted>December 7, 2016</results_first_submitted>
  <results_first_submitted_qc>March 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 14, 2017</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Imperial College Healthcare NHS Trust</investigator_affiliation>
    <investigator_full_name>Gillian Chumbley</investigator_full_name>
    <investigator_title>Consultant Nurse</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Thoracotomy</keyword>
  <keyword>VATS</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Saline</title>
          <description>Patients will receive a placebo infusion of 0.9% sodium chloride, which will start 10 minutes prior to the start of the operation and continue for 96 hours.</description>
        </group>
        <group group_id="P2">
          <title>Ketamine</title>
          <description>Patients will receive intravenous ketamine, starting 10 minutes prior to surgery and will continue for 96 hours
Ketamine: Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Weeks Afer Surgery</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Saline</title>
          <description>Patients will receive a placebo infusion of 0.9% sodium chloride, which will start 10 minutes prior to the start of the operation and continue for 96 hours.</description>
        </group>
        <group group_id="B2">
          <title>Ketamine</title>
          <description>Patients will receive intravenous ketamine, starting 10 minutes prior to surgery and will continue for 96 hours
Ketamine: Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.645" lower_limit="22" upper_limit="87"/>
                    <measurement group_id="B2" value="56.025" lower_limit="18" upper_limit="81"/>
                    <measurement group_id="B3" value="57.84" lower_limit="18" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Incidence of Pain</title>
        <description>Measures in pain include:
Numeric pain score of 0 to 10. Zero denotes 'no pain'; 10 denotes 'pain as bad as you can imagine'</description>
        <time_frame>6 weeks after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Saline</title>
            <description>Patients will receive a placebo infusion of 0.9% sodium chloride, which will start 10 minutes prior to the start of the operation and continue for 96 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ketamine</title>
            <description>Patients will receive intravenous ketamine, starting 10 minutes prior to surgery and will continue for 96 hours
Ketamine: Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of Pain</title>
          <description>Measures in pain include:
Numeric pain score of 0 to 10. Zero denotes 'no pain'; 10 denotes 'pain as bad as you can imagine'</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="2.06"/>
                    <measurement group_id="O2" value="2.02" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A power calculation expecting a reduction in pain of 2 points on a 10 point scale, at the 6 week assessment with alpha= 5%, 1- beta=90% and bi-lateral hypothesis required a sample size of 72 patient in each trial, 36 in each treatment group.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A power calculation expecting a reduction in pain of 2 points on a 10 point scale, at the 6 week assessment with alpha= 5%, 1- beta=90% and bi-lateral hypothesis required a sample size of 72 patient in each trial, 36 in each treatment group.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analgesic Consumption</title>
        <description>Analgesia consumption will be measured post-operatively and at the time points stated above. The cumulative dose of opioid, measured in oral morphine equivalents, will be obtained from the time of the patient’s arrival in recovery (T0), to 24 hours post-operatively (T0 + 24) and to 48 hours post-operatively (T0 + 48). Analgesia consumption will also be measured at six weeks, three months, six months and one year. All analgesia will be converted to oral morphine equivalents (in mg) by multiplication by a factor depending on the analgesia taken (codeine 0.15, tramadol 0.17, oxycodone 2)</description>
        <time_frame>24 hours, 48 hours, 6 weeks, 3, 6 and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensory Testing</title>
        <description>Hypoaesthesia: light touch of the blunt end of a paintbrush was felt less precisely, than in healthy tissue.
Hyperalgesia: the pain induced by a sterile neurotip, applied perpendicular to the skin is felt abnormally strongly, in comparison to the contralateral side.
Static allodynia: the application of a Von Frey hair number 14. (8g) was unpleasant, in comparison to the contralateral side.
Dynamic allodynia: three successive gentle strokes of an 8 mm-wide paintbrush over a 40 mm distance, is unpleasant, in comparison to the contralateral side.</description>
        <time_frame>6 weeks, 6 months, 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Side-effects</title>
        <description>The presence of nausea, vomiting, itching, sedation, feeling lightheaded or vivid dreams will be recorded at the above time points</description>
        <time_frame>24 hours, 48 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Pain</title>
        <description>Measures in pain include:
Numeric pain score of 0 to 10. Zero denotes 'no pain'; 10 denotes 'pain as bad as you can imagine' Brief Pain Inventory (BPI) Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS)</description>
        <time_frame>3, 6 and 12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For 96 hours the ketamine or placebo infusion was running and whilst the patient remained in hospital after surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Saline</title>
          <description>Patients will receive a placebo infusion of 0.9% sodium chloride, which will start 10 minutes prior to the start of the operation and continue for 96 hours.</description>
        </group>
        <group group_id="E2">
          <title>Ketamine</title>
          <description>Patients will receive intravenous ketamine, starting 10 minutes prior to surgery and will continue for 96 hours
Ketamine: Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <description>Hallucinations experienced post-operatively, mostly thought to be due to opioids</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea, infectious</sub_title>
                <description>Clostridium difficile confirmed</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Agitation postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>Patient developed renal failure 13 days after starting trial. Renal biopsy showed undetected myeloma.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <description>Patient developed respiratory distress after thoracotomy, re-intubated and ventilated</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lung hypoinflation</sub_title>
                <description>Lung collapse following thoracotomy for cancer, unable to oxygenate. Death due to respiratory failure.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <description>Injury post thoracotomy intubation, causing hoarse voice</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="52"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Post-operative vomiting</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Patients who felt lightheaded after surgery</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vivid dreams</sub_title>
                <description>Vivid dreams experienced after surgery</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="52"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Gillian Chumbley</name_or_title>
      <organization>ImperialNHSTrust</organization>
      <phone>+44 203 311 1000 ext Bleep 5865</phone>
      <email>gillian.chumbley@imperial.nhs.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

